Symbols

TCBP(Delisted)

TC BioPharm·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TCBP

Tc Biopharm (Holdings) Plc.

A biotechnology company that develops immunotherapies for cancer and infectious diseases

Industry

Established Date

10/25/2021

Listing Date

02/11/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.tcbiopharm.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, Scotland, United Kingdom

Business

Introduction

TC BioPharm (Holdings) plc., a company incorporated under the laws of Scotland on October 25, 2021. The company is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products based on the proprietary allogeneic gamma delta T (GD-T) cell platform. Leveraging the innate capabilities of GD-Ts, the company has been able to develop a range of clinical-stage cell therapies designed to combat cancer and viral infections.

Company Financials

EPS

TCBP has released its 2021 Q4 earnings. EPS was reported at -0.27, versus the expected 0, missing expectations. The chart below visualizes how TCBP has performed over recent quarters, highlighting trends in earnings surprises.